Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
South Korea · Delayed Price · Currency is KRW 84,900
-500 (-0.59%)
At close: Jul 22, 2025, 3:30 PM KST
KRX:185750 Revenue
Chong Kun Dang Pharmaceutical had revenue of 400.96B KRW in the quarter ending March 31, 2025, with 10.91% growth. This brings the company's revenue in the last twelve months to 1.63T, down -2.39% year-over-year. In the year 2024, Chong Kun Dang Pharmaceutical had annual revenue of 1.59T, down -4.97%.
Revenue (ttm)
1,625.88B
Revenue Growth
-2.39%
P/S Ratio
0.69
Revenue / Employee
712.79M
Employees
2,281
Market Cap
1,118.65B
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,898.69B |
| Celltrion | 3,662.23B |
| ALTEOGEN | 151.65B |
| Yuhan | 2,114.76B |
| SK Biopharmaceuticals | 578.00B |
| Peptron | 4.30B |
| HLB Co., Ltd. | 74.64B |
| PharmaResearch | 392.31B |